Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia

Abstract Background Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-month survival of decompensated cirrhotic patients with and without h...

Full description

Bibliographic Details
Published in:	BMC Gastroenterology
Main Authors:	Shuzhen Wang, Xin Zhang, Tao Han, Wen Xie, Yonggang Li, Hong Ma, Roman Liebe, Honglei Weng, Hui-Guo Ding
Format:	Article
Language:	English
Published:	BMC 2018-09-01
Subjects:	Ascites Hyponatremia Liver cirrhosis Survival Tolvaptan
Online Access:	http://link.springer.com/article/10.1186/s12876-018-0857-0

Similar Items

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
by: Jieting Tang, et al.
Published: (2020-11-01)

Tolvaptan Improves Refractory Ascites and Overall Survival in Cirrhosis: A Meta-Analysis
by: Chetan Kalal, et al.
Published: (2025-01-01)

Plasma copeptin concentration is a predictor of tolvaptan efficacy in patients with hepatic ascites
by: Fumimasa Tomooka, et al.
Published: (2023-09-01)

The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia
by: Fatih Kahraman, et al.
Published: (2015-04-01)

Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis
by: Ashraf Abd El-Khalik Barakat, et al.
Published: (2015-10-01)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
by: Shunsuke Shiba, et al.
Published: (2020-03-01)

Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand
by: Permsuwan U, et al.
Published: (2025-07-01)

Efficacy of vaptans for correction of postoperative hyponatremia: A comparison between single intravenous bolus conivaptan vs oral tolvaptan
by: Sunil Rajan, et al.
Published: (2018-01-01)

Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey
by: Saim Sağ, et al.
Published: (2017-07-01)

ASCITES IN THE CIRRHOTIC PATIENT: HOW TO APPROACH IT? (IN SPANISH)
by: Yepes-Barreto Ismael, et al.
Published: (2014-06-01)

Use of 'Vaptans' in treatment of hyponatremia
by: Aslı Tanındı, et al.
Published: (2015-04-01)

Severe tolvaptan-associated hyperglycemia: a case report
by: Huihuan Sun, et al.
Published: (2025-07-01)

A prospective study to compare the clinical efficacy of Tolvaptan with 3% hypertonic saline solution in hospitalized patients having hyponatremia
by: Jobin Kunjumon Vilapurathu, et al.
Published: (2014-01-01)

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
by: Jun Jae Kim, et al.
Published: (2014-03-01)

Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India
by: Soumya Patra, et al.
Published: (2014-01-01)

Non-Cirrhotic Ascites: Causes and Management
by: Paul Carrier, et al.
Published: (2024-10-01)

Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD
by: Anna Arecco, et al.
Published: (2024-01-01)

Effectiveness of albumin infusion for the management of hyponatremia in decompensated cirrhosis: a systematic review
by: Akash Roy, et al.
Published: (2024-06-01)

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis
by: Hongzhong Liu, et al.
Published: (2024-01-01)

Extracorporal modified ascitic fluid reinfusion in treatment of resistant ascites in liver cirrhosis
by: I. E. Onnintsev, et al.
Published: (2017-06-01)

Importance of early use of tolvaptan in hyponatremic acutely decompensated heart failure patients, a retrospective study
by: Rarsari Soerarso, et al.
Published: (2025-01-01)

Ascites
by: Soung Won Jeong
Published: (2018-08-01)

Prevalence and predictors for spontaneous bacterial peritonitis in cirrhotic patients with ascites admitted at medical block in Korle-Bu Teaching Hospital, Ghana
by: Amoako Duah, et al.
Published: (2019-05-01)

Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report
by: Hiroya Iida, et al.
Published: (2020-03-01)

Transjugular Portosystemic Shunting in Refractory Cirrhotic Ascites
by: Yu. V. Khoronko, et al.
Published: (2021-04-01)

Teaching Points: Appropriate Evaluation of Ascitic Fluid in an Acutely Ill Cirrhotic Patient
by: Laila Khan, et al.
Published: (2019-08-01)

Effect of vasopressin V2-receptor antagonist tolvaptan on syndrome of inappropriate antidiuresis (SIAD) after transsphenoidal pituitary surgery: recovery of measured osmolality
by: Masahiko Tosaka, et al.
Published: (2022-10-01)

Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor
by: Shota Hiroshima, et al.
Published: (2021-04-01)

A STUDY OF HYPONATREMIA IN PATIENTS OF LIVER CIRRHOSIS IN A TERTIARY CARE HOSPITAL OF SOUTH GUJARAT
by: Urvi B Patel, et al.
Published: (2021-03-01)

A Metabolomic Analysis of Cirrhotic Ascites
by: Diren Beyoğlu, et al.
Published: (2022-06-01)

Evidence-based hyponatremia management in liver disease
by: Ji Young Ryu, et al.
Published: (2023-10-01)

A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database
by: Daisuke Hagiwara, et al.
Published: (2023-12-01)

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons
by: Yuan Gao, et al.
Published: (2024-11-01)

Effect of Ayurveda Management on Liver Cirrhosis with Ascites-A Retrospective Cohort Study
by: B.R. Tubaki, et al.
Published: (2022-04-01)

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
by: Ji Young Ryu, et al.
Published: (2023-10-01)

Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis
by: Dhan Bahadur Shrestha, et al.
Published: (2021-12-01)

Combination of PCT, sNFI and dCHC for the diagnosis of ascites infection in cirrhotic patients
by: Han Wang, et al.
Published: (2018-08-01)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01)

Relationship between Absolute Lymphocyte Count and Ascites in Patients with Liver Cirrhosis
by: Nathasya Rizkyana Riyadi, et al.
Published: (2024-01-01)

RESPIRATORY AND SYMPTOMATIC IMPACT OF ASCITES RELIEF BY PARACENTESIS IN PATIENTS WITH HEPATIC CIRRHOSIS
by: Verônica Lourenço WITTMER, et al.
Published: (2020-02-01)